Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Common Stock
NRBO | US
2.92
USD-0.11
-3.63%
NRBO | US
About Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.92
Open
3.04
High
3.15
Low
2.92
NeuroBo Pharmaceuticals Inc. a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241 a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726 a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001 a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Boston Massachusetts.
View LessNRBO | US
Risk
89.3
Sharpe
-0.25
Luna's Score
51/100
Recommendation
Hold
Luna says (NRBO | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
104.5%1 month
89.3%3 months
77.9%6 months
72.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.42
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
-0.43
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-26.51M
MarketCap
24.78M
MarketCap(USD)
24.78M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-117.36
Short ratio
0.57
Short perc.
1.05
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.19
Range1M
1.42
Range3M
2.64
Volumes: Market Activity
Rel. volume
0.26
Price X volume
46.49K
